Aigen Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Aigen Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,739	Closed	-$1.66M	–	790
2022 Q1	$1.66M	Buy	+15,739	New	+$1.53M	0.29%	102
2021 Q4	–	Sell	-1,836	Closed	-$201K	–	1231
2021 Q3	$201K	Buy	+1,836	New	+$191K	0.04%	425
2020 Q1	–	Sell	-34	Closed	-$1K	–	1723
2019 Q4	$1K	Buy	+34	New	+$1.04K	﹤0.01%	1100

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Aigen Investment Management's HZNP Position: Q2 2022 in Review

Aigen Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 15,739 shares — an estimated $1.66M sold.

Aigen Investment Management first reported a position in HZNP in Q4 2019 and held it in 3 quarters. The position peaked at $1.66M in Q1 2022. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Aigen Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Aigen Investment Management sold 15,739 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $1.66M.
Aigen Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 3 quarters.
Aigen Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.66M in Q1 2022.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Aigen Investment Management's 13F filing for Q2 2022, filed 2 Aug 2022.